67
Participants
Start Date
January 31, 2012
Primary Completion Date
December 31, 2012
Study Completion Date
March 31, 2014
Placebo
Daily subcutaneous administration for 8 hours a day for 10 days
rhNRG-1 Dose 1
Daily subcutaneous administration for 8 hours a day for 10 days
rhNRG-1 Dose 2
Daily subcutaneous administration for 8 hours a day for 10 days
Sentara Cardiovascular Research Institute, Norfolk
University of South Florida, Tampa
Clearwater Cardiovascular & Interventional Consultants, MD, PA, Clearwater
University of Iowa Hospitals and Clinics, Iowa City
Benchmark Research, Metairie
MedPharmics, LLC., Kenner
The Medical Center of Plano, Plano
East Texas Cardiology, Houston
University of Colorado Denver, Denver
Metabolic Clinic and Research Center, Los Angeles
USC Cardiovascular Division, Los Angeles
University of California, San Diego, La Jolla
Orange County Research Center, Tustin
Zensun USA Inc.
INDUSTRY
Zensun Sci. & Tech. Co., Ltd.
INDUSTRY